title: Incidence of cervical squamous intraepithelial lesions in HIV-infected women.
abstract: BACKGROUND
  Women infected with human immunodeficiency virus (HIV) are at increased risk for cervical squamous intraepithelial lesions (SILs), the precursors to invasive cervical cancer. However, little is known about the causes of this association.
  
  
  OBJECTIVE
  To compare the incidence of SILs in HIV-infected vs uninfected women and to determine the role of risk factors in the pathogenesis of such lesions.
  
  
  METHODS
  Prospective cohort study conducted from October 1,1991, to June 30, 1996.
  
  
  METHODS
  Urban clinics for sexually transmitted diseases, HIV infection, and methadone maintenance.
  
  
  METHODS
  A total of 328 HIV-infected and 325 uninfected women with no evidence of SILs by Papanicolaou test or colposcopy at study entry.
  
  
  METHODS
  Incident SILs confirmed by biopsy, compared by HIV status and risk factors.
  
  
  RESULTS
  During about 30 months of follow-up, 67 (20%) HIV-infected and 16 (5%) uninfected women developed a SIL (incidence of 8.3 and 1.8 cases per 100 person-years in sociodemographically similar infected and uninfected women, respectively [P<.001]). Of incident SILs, 91% were low grade in HIV-infected women vs 75% in uninfected women. No invasive cervical cancers were identified. By multivariate analysis, significant risk factors for incident SILs were HIV infection (relative risk [RR], 3.2; 95% confidence interval [CI], 1.7-6.1), transient human papillomavirus (HPV) DNA detection (RR, 5.5; 95% CI, 1.4-21.9), persistent HPV DNA types other than 16 or 18 (RR, 7.6; 95% CI, 1.9-30.3), persistent HPV DNA types 16 and 18 (RR, 11.6; 95% CI, 2.7-50.7), and younger age (<37.5 years; RR, 2.1; 95% CI, 1.3-3.4).
  
  
  CONCLUSIONS
  In our study, 1 in 5 HIV-infected women with no evidence of cervical disease developed biopsy-confirmed SILs within 3 years, highlighting the importance of cervical cancer screening programs in this population.
authors.affiliation: Division of HIV/AIDS Prevention, Surveillance, and Epidemiology, National Center for HIV, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA, USA.
authors.forename: T V
authors.initials: TV
authors.lastname: Ellerbrock
authors.forename: M A
authors.initials: MA
authors.lastname: Chiasson
authors.forename: T J
authors.initials: TJ
authors.lastname: Bush
authors.forename: X W
authors.initials: XW
authors.lastname: Sun
authors.forename: D
authors.initials: D
authors.lastname: Sawo
authors.forename: K
authors.initials: K
authors.lastname: Brudney
authors.forename: T C
authors.initials: TC
authors.lastname: Wright
mesh_terms: D000328:Adult; D005260:Female; D015658:HIV Infections / Q000150:complications*; D006801:Humans; D015994:Incidence; D015999:Multivariate Analysis; D027383:Papillomaviridae; D030361:Papillomavirus Infections / Q000150:complications; D016016:Proportional Hazards Models; D011446:Prospective Studies; D012307:Risk Factors; D012959:Socioeconomic Factors; D014412:Tumor Virus Infections / Q000150:complications; D014481:United States / Q000453:epidemiology; D002583:Uterine Cervical Neoplasms / Q000150:complications* / Q000453:epidemiology* / Q000821:virology; D002578:Uterine Cervical Dysplasia / Q000150:complications* / Q000453:epidemiology* / Q000821:virology